Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Nuclear trafficking of the HIV-1 pre-integration complex depends on the ADAM10 intracellular domain.

Endsley MA, Somasunderam AD, Li G, Oezguen N, Thiviyanathan V, Murray JL, Rubin DH, Hodge TW, O'Brien WA, Lewis B, Ferguson MR.

Virology. 2014 Apr;454-455:60-6. doi: 10.1016/j.virol.2014.02.006. Epub 2014 Feb 22.

2.

Identification of cellular proteins required for replication of human immunodeficiency virus type 1.

Dziuba N, Ferguson MR, O'Brien WA, Sanchez A, Prussia AJ, McDonald NJ, Friedrich BM, Li G, Shaw MW, Sheng J, Hodge TW, Rubin DH, Murray JL.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1329-39. Epub 2012 Apr 20.

3.

Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis.

Murray JL, McDonald NJ, Sheng J, Shaw MW, Hodge TW, Rubin DH, O'Brien WA, Smee DF.

Antivir Chem Chemother. 2012 May 14;22(5):205-15. doi: 10.3851/IMP2080.

PMID:
22374988
4.

A functional role for ADAM10 in human immunodeficiency virus type-1 replication.

Friedrich BM, Murray JL, Li G, Sheng J, Hodge TW, Rubin DH, O'Brien WA, Ferguson MR.

Retrovirology. 2011 May 11;8:32. doi: 10.1186/1742-4690-8-32.

5.

Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

Trivedi V, Von Lindern J, Montes-Walters M, Rojo DR, Shell EJ, Parkin N, O'Brien WA, Ferguson MR.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1291-300. doi: 10.1089/aid.2007.0244.

6.

A critical role for CD63 in HIV replication and infection of macrophages and cell lines.

Chen H, Dziuba N, Friedrich B, von Lindern J, Murray JL, Rojo DR, Hodge TW, O'Brien WA, Ferguson MR.

Virology. 2008 Sep 30;379(2):191-6. doi: 10.1016/j.virol.2008.06.029. Epub 2008 Aug 5.

7.

Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Goetz MB, Ferguson MR, Han X, McMillan G, St Clair M, Pappa KA, McClernon DR, O'Brien WA.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):541-9.

8.

Saquinavir/Ritonavir: its evolution and current treatment role.

O'Brien WA 3rd.

AIDS Read. 2006 Jan;16(1):38-44; discussion 43. Review.

PMID:
16433471
9.

Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase.

Somasunderam A, Ferguson MR, Rojo DR, Thiviyanathan V, Li X, O'Brien WA, Gorenstein DG.

Biochemistry. 2005 Aug 2;44(30):10388-95.

10.

Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults.

Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, Holder PF, O'Brien WA, Whitney CG, Butler JC, Breiman RF.

Clin Diagn Lab Immunol. 2004 Jan;11(1):137-41.

12.

Potential role for CD63 in CCR5-mediated human immunodeficiency virus type 1 infection of macrophages.

von Lindern JJ, Rojo D, Grovit-Ferbas K, Yeramian C, Deng C, Herbein G, Ferguson MR, Pappas TC, Decker JM, Singh A, Collman RG, O'Brien WA.

J Virol. 2003 Mar;77(6):3624-33.

13.

Special issues in the management of patients with ESRD and HIV infection.

Ahuja TS, O'brien WA.

Am J Kidney Dis. 2003 Feb;41(2):279-91. Review.

PMID:
12552489
14.

HIV-1 replication cycle.

Ferguson MR, Rojo DR, von Lindern JJ, O'Brien WA.

Clin Lab Med. 2002 Sep;22(3):611-35. Review.

PMID:
12244589
15.

Viral load response to a pneumococcal conjugate vaccine, polysaccharide vaccine or placebo among HIV-infected patients.

Goetz MB, Feikin DR, Lennox JL, O'Brien WA, Elie CM, Butler JC, Breiman RF.

AIDS. 2002 Jul 5;16(10):1421-3.

PMID:
12131220
16.

Genotypic HIV-1 drug resistance testing in antiretroviral-naive subjects in Houston, Texas.

Nannini EC, Han X, O'Brien WA, Arduino RC.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):317-9. No abstract available.

PMID:
11873085
17.

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults.

Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, Holder PF, O'Brien WA, Whitney CG, Butler JC, Breiman RF.

Vaccine. 2001 Nov 12;20(3-4):545-53.

PMID:
11672921
19.

Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence.

Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O'Brien WA, Herbein G.

J Immunol. 2000 Dec 1;165(11):6437-46.

20.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
21.

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E.

J Virol. 2000 Sep;74(18):8358-67.

22.

Resistance against reverse transcriptase inhibitors.

O'Brien WA.

Clin Infect Dis. 2000 Jun;30 Suppl 2:S185-92. Review.

PMID:
10860904
23.

Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis.

Herbein G, O'Brien WA.

Proc Soc Exp Biol Med. 2000 Mar;223(3):241-57. Review.

PMID:
10719836
24.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
25.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, Pumarola T, Gallart T, Miró JM, Gatell JM.

AIDS. 1999 Jul 30;13(11):F79-86.

PMID:
10449278
26.

Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions.

Suzuki Y, Koyanagi Y, Tanaka Y, Murakami T, Misawa N, Maeda N, Kimura T, Shida H, Hoxie JA, O'Brien WA, Yamamoto N.

J Virol. 1999 Jan;73(1):316-24.

27.

Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.

Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, Caligiuri MA.

J Immunol. 1998 Dec 1;161(11):6433-8.

28.

Effect of oral beta-carotene supplementation on plasma human immunodeficiency virus (HIV) RNA levels and CD4+ cell counts in HIV-infected patients.

Nimmagadda AP, Burri BJ, Neidlinger T, O'Brien WA, Goetz MB.

Clin Infect Dis. 1998 Nov;27(5):1311-3.

PMID:
9827288
29.

Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor.

Grovit-Ferbas K, Ferbas J, Gudeman V, Sadeghi S, Goetz MB, Giorgi JV, Chen IS, O'Brien WA.

J Virol. 1998 Nov;72(11):8650-8.

30.

Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4.

Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, O'Brien WA, Verdin E.

Nature. 1998 Sep 10;395(6698):189-94.

PMID:
9744279
31.

Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial.

Tasker SA, O'Brien WA, Treanor JJ, Weiss PJ, Olson PE, Kaplan AH, Wallace MR.

Vaccine. 1998 May-Jun;16(9-10):1039-42.

PMID:
9682356
32.

Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.

Arnó A, Ruiz L, Juan M, Zayat MK, Puig T, Balagué M, Romeu J, Pujol R, O'Brien WA, Clotet B.

AIDS. 1998 May 7;12(7):697-704.

PMID:
9619800
33.

The significance of vitamin A and carotenoid status in persons infected by the human immunodeficiency virus.

Nimmagadda A, O'Brien WA, Goetz MB.

Clin Infect Dis. 1998 Mar;26(3):711-8. Review.

PMID:
9524850
34.

The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients.

Stringer WW, Berezovskaya M, O'Brien WA, Beck CK, Casaburi R.

Med Sci Sports Exerc. 1998 Jan;30(1):11-6.

PMID:
9475639
35.

A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.

Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA.

J Exp Med. 1997 Oct 20;186(8):1395-400.

36.
37.

Human immunodeficiency virus type 1 activation after blood transfusion.

Mudido PM, Georges D, Dorazio D, Yen-Lieberman B, Bae S, O'Brien WA, Spritzler J, Lederman MM.

Transfusion. 1996 Oct;36(10):860-5.

PMID:
8863771
38.

HIV viral load markers in clinical practice.

Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA.

Nat Med. 1996 Jun;2(6):625-9. Review.

PMID:
8640545
39.

Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions.

O'Brien WA, Sumner-Smith M, Mao SH, Sadeghi S, Zhao JQ, Chen IS.

J Virol. 1996 May;70(5):2825-31.

40.

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD.

N Engl J Med. 1996 Feb 15;334(7):426-31.

41.

Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.

Simberkoff MS, Hartigan PM, Hamilton JD, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM, Hawkes CA, Jensen PC, Kilmas NG, Labriola AM, O'Brien WA, Oster CN, Weinhold KJ, Wray NP, Pazner SB.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):142-50.

PMID:
8556396
42.

Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination.

O'Brien WA, Grovit-Ferbas K, Namazi A, Ovcak-Derzic S, Wang HJ, Park J, Yeramian C, Mao SH, Zack JA.

Blood. 1995 Aug 1;86(3):1082-9.

PMID:
7620162
43.

HIV-1 entry and reverse transcription in macrophages.

O'Brien WA.

J Leukoc Biol. 1994 Sep;56(3):273-7. Review.

PMID:
8083599
45.
46.

Genetic and biologic basis of HIV-1 neurotropism.

O'Brien WA.

Res Publ Assoc Res Nerv Ment Dis. 1994;72:47-70. Review. No abstract available.

PMID:
8115721
47.

Rapid enzymatic analysis for human immunodeficiency virus type 1 DNA in clinical specimens.

Sevall JS, Prince H, Garratty G, O'Brien WA, Zack JA.

Clin Chem. 1993 Mar;39(3):433-9.

48.
49.
50.

Viral determinants of cellular tropism.

O'Brien WA.

Pathobiology. 1992;60(4):225-33. Review.

PMID:
1388720

Supplemental Content

Loading ...
Support Center